These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 24004669)

  • 1. PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma.
    Boi M; Rinaldi A; Kwee I; Bonetti P; Todaro M; Tabbò F; Piva R; Rancoita PM; Matolcsy A; Timar B; Tousseyn T; Rodríguez-Pinilla SM; Piris MA; Beà S; Campo E; Bhagat G; Swerdlow SH; Rosenwald A; Ponzoni M; Young KH; Piccaluga PP; Dummer R; Pileri S; Zucca E; Inghirami G; Bertoni F
    Blood; 2013 Oct; 122(15):2683-93. PubMed ID: 24004669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.
    Abate F; Todaro M; van der Krogt JA; Boi M; Landra I; Machiorlatti R; Tabbò F; Messana K; Abele C; Barreca A; Novero D; Gaudiano M; Aliberti S; Di Giacomo F; Tousseyn T; Lasorsa E; Crescenzo R; Bessone L; Ficarra E; Acquaviva A; Rinaldi A; Ponzoni M; Longo DL; Aime S; Cheng M; Ruggeri B; Piccaluga PP; Pileri S; Tiacci E; Falini B; Pera-Gresely B; Cerchietti L; Iqbal J; Chan WC; Shultz LD; Kwee I; Piva R; Wlodarska I; Rabadan R; Bertoni F; Inghirami G;
    Leukemia; 2015 Jun; 29(6):1390-401. PubMed ID: 25533804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation.
    Merkel O; Hamacher F; Griessl R; Grabner L; Schiefer AI; Prutsch N; Baer C; Egger G; Schlederer M; Krenn PW; Hartmann TN; Simonitsch-Klupp I; Plass C; Staber PB; Moriggl R; Turner SD; Greil R; Kenner L
    J Pathol; 2015 Aug; 236(4):445-56. PubMed ID: 25820993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EMMPRIN (CD147) is induced by C/EBPβ and is differentially expressed in ALK+ and ALK- anaplastic large-cell lymphoma.
    Schmidt J; Bonzheim I; Steinhilber J; Montes-Mojarro IA; Ortiz-Hidalgo C; Klapper W; Fend F; Quintanilla-Martínez L
    Lab Invest; 2017 Sep; 97(9):1095-1102. PubMed ID: 28581487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
    Werner MT; Zhao C; Zhang Q; Wasik MA
    Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma.
    Eckerle S; Brune V; Döring C; Tiacci E; Bohle V; Sundström C; Kodet R; Paulli M; Falini B; Klapper W; Chaubert AB; Willenbrock K; Metzler D; Bräuninger A; Küppers R; Hansmann ML
    Leukemia; 2009 Nov; 23(11):2129-38. PubMed ID: 19657361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations.
    Zettl A; Rüdiger T; Konrad MA; Chott A; Simonitsch-Klupp I; Sonnen R; Müller-Hermelink HK; Ott G
    Am J Pathol; 2004 May; 164(5):1837-48. PubMed ID: 15111330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma.
    Liu C; Iqbal J; Teruya-Feldstein J; Shen Y; Dabrowska MJ; Dybkaer K; Lim MS; Piva R; Barreca A; Pellegrino E; Spaccarotella E; Lachel CM; Kucuk C; Jiang CS; Hu X; Bhagavathi S; Greiner TC; Weisenburger DD; Aoun P; Perkins SL; McKeithan TW; Inghirami G; Chan WC
    Blood; 2013 Sep; 122(12):2083-92. PubMed ID: 23801630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of putative pathogenic microRNA and its downstream targets in anaplastic lymphoma kinase-negative anaplastic large cell lymphoma.
    Mehrotra M; Medeiros LJ; Luthra R; Sargent RL; Yao H; Barkoh BA; Singh R; Patel KP
    Hum Pathol; 2014 Oct; 45(10):1995-2005. PubMed ID: 25128227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.
    Boi M; Todaro M; Vurchio V; Yang SN; Moon J; Kwee I; Rinaldi A; Pan H; Crescenzo R; Cheng M; Cerchietti L; Elemento O; Riveiro ME; Cvitkovic E; Bertoni F; Inghirami G;
    Oncotarget; 2016 Nov; 7(48):79637-79653. PubMed ID: 27793034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma.
    Merkel O; Hamacher F; Laimer D; Sifft E; Trajanoski Z; Scheideler M; Egger G; Hassler MR; Thallinger C; Schmatz A; Turner SD; Greil R; Kenner L
    Proc Natl Acad Sci U S A; 2010 Sep; 107(37):16228-33. PubMed ID: 20805506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment and characterization of TK-ALCL1: a novel NPM-ALK-positive anaplastic large-cell lymphoma cell line.
    Sungwan P; Panaampon J; Kariya R; Kamio S; Nakagawa R; Hirozane T; Ogura Y; Abe M; Hirabayashi K; Fujiwara Y; Kikuta K; Okada S
    Hum Cell; 2024 Jul; 37(4):1215-1225. PubMed ID: 38755432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.
    Drexler HG; Gignac SM; von Wasielewski R; Werner M; Dirks WG
    Leukemia; 2000 Sep; 14(9):1533-59. PubMed ID: 10994999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas.
    Boi M; Zucca E; Inghirami G; Bertoni F
    Br J Haematol; 2015 Mar; 168(6):771-83. PubMed ID: 25559471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
    Eyre TA; Khan D; Hall GW; Collins GP
    Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes.
    Lamant L; de Reyniès A; Duplantier MM; Rickman DS; Sabourdy F; Giuriato S; Brugières L; Gaulard P; Espinos E; Delsol G
    Blood; 2007 Mar; 109(5):2156-64. PubMed ID: 17077326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts.
    Scarfò I; Pellegrino E; Mereu E; Kwee I; Agnelli L; Bergaggio E; Garaffo G; Vitale N; Caputo M; Machiorlatti R; Circosta P; Abate F; Barreca A; Novero D; Mathew S; Rinaldi A; Tiacci E; Serra S; Deaglio S; Neri A; Falini B; Rabadan R; Bertoni F; Inghirami G; Piva R;
    Blood; 2016 Jan; 127(2):221-32. PubMed ID: 26463425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis.
    Martinengo C; Poggio T; Menotti M; Scalzo MS; Mastini C; Ambrogio C; Pellegrino E; Riera L; Piva R; Ribatti D; Pastorino F; Perri P; Ponzoni M; Wang Q; Voena C; Chiarle R
    Cancer Res; 2014 Nov; 74(21):6094-106. PubMed ID: 25193384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 and β-Catenin Expression Predict Poorer Prognosis in Patients With Anaplastic Large-Cell Lymphoma.
    Richardson AI; Yin CC; Cui W; Li N; Medeiros LJ; Li L; Zhang D
    Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e385-e392. PubMed ID: 31078446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PRDM1/BLIMP1: a tumor suppressor gene in B and T cell lymphomas.
    Boi M; Zucca E; Inghirami G; Bertoni F
    Leuk Lymphoma; 2015 May; 56(5):1223-8. PubMed ID: 25115512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.